Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GDA 201

Drug Profile

GDA 201

Alternative Names: GDA-201; NAM NK cells - Gamida; NAM-NK Cells; Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Latest Information Update: 28 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gamida-Cell
  • Developer Gamida-Cell; University of Minnesota
  • Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma; Non-Hodgkin's lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 21 May 2020 Updated efficacy data from a phase I trial in Non-Hodgkin's lymphoma and Multiple myeloma released by Gamida Cell
  • 25 Feb 2020 Gamida Cell plans to submit IND application to the US FDA for Non-Hodgkins Lymphoma in the fourth quarter of 2020
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top